Press releases
 |
| << Back |
| Dyax Corp. to Present at the 2010 Future Leaders in the Biotech Industry Conference |
CAMBRIDGE, Mass., Apr 05, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that George Migausky, Executive Vice President and Chief Financial Officer of Dyax, will present at the BioCentury and ThomsonReuters 17th Annual Future Leaders in the Biotech Industry Conference, being held April 8th at the Millennium Broadway Hotel in New York City. Mr. Migausky will present a corporate progress report, including an update on the Company's commercial activities for KALBITOR(R) (ecallantide) and clinical development programs. The Dyax presentation is scheduled for Thursday, April 8th at 1:30 PM (ET). The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at http://www.dyax.com. The 25-minute presentation will also be available on the Dyax website for a limited period of time following the conference. About Dyax Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Dyax's first product, KALBITOR(R) (ecallantide), is available in the United States for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. Dyax's lead product candidate is DX-88, a recombinant, small protein that is being evaluated for its therapeutic potential in other angioedema indications (acquired and ACE inhibitor-induced angioedemas). DX-88 is also being evaluated through Dyax's partner, Fovea Pharmaceuticals (sanofi aventis), which is in a Phase 1 trial for retinal vein occlusion-induced macular edema. DX-88 and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit http://www.dyax.com. SOURCE: Dyax Corp. Dyax Corp. |
|
